ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the first patient has been treated in a global Phase 3 clinical trial of IMC-1121B, its anti-vascular endothelial growth factor receptor-2 (VEGFR-2) IgG1 monoclonal antibody, in women with metastatic breast cancer.
Publ.Date : Mon, 18 Aug 2008 02:00:00 PDT
Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.
Publ.Date : Wed, 13 Aug 2008 02:00:00 PDT
Research by scientists at the University of Sheffield suggests that the combination of zoledronic acid (a drug used to prevent bone loss) and chemotherapy agent doxorubicin could stop the growth of breast cancer tumours. Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "Breakthrough welcomes any research which investigates new uses for existing treatments to help benefit people with breast cancer.
Publ.Date : Fri, 15 Aug 2008 04:00:00 PDT
Scientists in the UK and Finland have discovered that a new combination of the chemotherapy drug doxorubicin and the bone-protecting drug zoledronic acid, both of which are considerably cheaper than herceptin, stopped breast cancer tumors growing in mice. Experts suggest that since both drugs are already in use, and if the combination proves effective and safe in human clinical trials, it should not take as long for it to be available as a new treatment for patients.
Publ.Date : Wed, 13 Aug 2008 08:00:00 PDT
A decade-long Nebraska study that showed disparities in breast and cervical cancer screenings could have spurred changes that raised the percentage of women screened in the state. "Disparities in screening between racial and ethnic groups, even in a homogeneous state such as Nebraska, are a problem and by digging into some of the differences we were able to have an impact on breast and cervical cancer screening," said lead study author Shingairai Feresu, Ph.D.
Publ.Date : Sat, 16 Aug 2008 01:00:00 PDT
|
